How do you approach the use of teclistamab plus daratumumab in patients with relapsed/refractory multiple myeloma who have previously been exposed to daratumumab or isatuximab?

If the last exposure to daratumumab or isatuximab was at least 6 months prior to relapse (CD38- exposed but not refractory), I would give consideration to a combination of teclistamab and daratumumab for the relapsed disease. If patients are actively progressing while on daratumumab or isatuximab th...

The treatment of patients at first relapse has changed dramatically over the last few years - first with the option of Carvykti (cilta-cel) for fit patients, and now the option of teclistamab-based regimens. At first we were only able to use teclistamab + daratamumab as a result of MajesTEC-3, and m...

I typically use a CD38 monoclonal antibody in combination with a BCMA-CD3 bispecific in patients who are exposed but not refractory to prior CD38 therapy, but I do not use the combination in patients who are refractory to a CD38 antibody. While there may be mechanistic synergy between the two classe...

MajesTEC-3 required no daratumumab refractoriness for enrollment. Per IMWG, this means no progression on or within 60 days of daratumumab. However, only 5% of the patients enrolled had prior daratumumab.

In addition to its anti-myeloma effects, daratumumab might make bispecific antibodies more effect...